ERBB2 and cancer: Similar to the hinge cysteine conjugates, the site-specific single cysteine based ADCs showed excellent potency against high Her2 expressing N87 cell lines (0.4 to 9 nM, Table 1), but were not potent against the moderate Her2 expressing 361 cancer cell line (IC50 >800 nM).